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Abstract: A significant percentage of elderly subjects (50%–80%) suffering from sub-acute 
ischemic cerebrovascular disease, with or without moderate or severe cognitive memory 
decline and with or without associated behavioral and psychological symptoms, shows a com-
plex syndrome. This syndrome is related to the progressive impairment of health conditions 
and/or stressing events (ie, hospitalization), characterized by confusion and/or stupor, which 
are consequently difficult to manage and require a great deal of care. Geriatric patients often 
suffer from multiple chronic illnesses, may take numerous medications daily, exhibit clinical 
instability, and may experience worsening of medical conditions following cerebral ischemic 
events and thus have an increased risk of disability and mortality. There are several studies in 
literature which demonstrate the efficacy of citicoline, thanks to its neuroprotective function, 
for the recovery and in postischemic cerebral rehabilitation. It has been shown that, even soon 
after an ischemic stroke, administration of oral citicoline (500–4000 mg/day) improves the 
general conditions evaluated with the Rankin scale and the National Institute of Health Stroke 
Scale 12. In particular, it has been shown that the CDP-choline improves the cognitive and 
mental performance in Alzheimer’s dementia and vascular dementia. We have evaluated the 
administration of citicoline in geriatric patients following a protocol of intravenous study on 
improvement of individual performances.
Keywords: geriatric syndrome, citicoline, Alzheimer’s disease, cerebrovascular disease, 
comorbidities
Introduction
The aging population
The number of people aged over 65-years old is increasing rapidly. The percentage of 
elderly people has increased from 11.4% in 1984 to over 18% in 2011 and is estimated 
to reach 35% in 2050.1
Today, 3.5% of those over 65-years old are aged over 80; since 1984 the number 
has increased from 1.2 million to 2.4 million and in 2050 this will reach 5 million;1 of 
these, 50% will be suffering from concurrent diseases and will be chronically disabled. 
Frail elderly patients whose health is worsening usually seek care from a general 
practitioner and then, in the case of complex clinical care, to the service network 
(specialist’s and home visits, nursing home, hospital, and so on).
A significant percentage of elderly subjects (50%–80%) with chronic ischemic 
cerebrovascular disease with or without moderate-to-severe cognitive decline, and with 
or without behavioral and psychological disorders, show complex symptoms related to 
the progressive deterioration of their general state of health and/or to situations causing 
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an increase in stress (eg, institutionalization). Symptoms are 
characterized by confusion and/or stupor, which are difficult 
to manage clinically and require a great deal of care.
Notes on citicoline
Citicoline (CDP-choline and choline or cytidine-5′-
diphosphate choline) works as an intermediate compound 
in the biosynthesis of cell membrane phospholipids and has 
got cholinergic and neuroprotective actions.2–4 CDP-choline 
(cytidine-5′-diphosphate choline) is an essential precursor 
for the synthesis of phosphatidylcholine, a component of the 
cell membrane that, during cerebral ischemia, is degraded 
into fatty acids and free radicals.2–4 This was widely demon-
strated in animal models which have shown that CDP-choline 
may protect cell membranes by accelerating phospholipid 
resynthesis.5 It can also reduce the progression of cell isch-
emic damage by suppressing the release of free fatty acids.6 
CDP-choline supplementation has been shown to play an 
important protective role in case of vascular damage and 
neurodegeneration, whereas in aging, normal rats there was 
no improved effect on memory. Therefore, these findings 
suggest that young rats with long-term memory impairment, 
due to selective hippocampal damage, benefit from a dietary 
supplementation of CDP-choline.5
CDP-choline is an endogenous compound normally 
produced by the body; when it is introduced as a drug, it is 
called citicoline.7 Citicoline inhibits apoptosis associated 
with cerebral ischemia and several models of neurode-
generation and it is able to strengthen neuroplasticity.7 
Citicoline:
•	 activates the biosynthesis of phospholipids in neuronal 
membranes
•	 increases brain metabolism
•	 increases norepinephrine and dopamine levels in the 
central nervous system
•	 has neuroprotective effects during hypoxia and 
ischemia
•	 improves learning and cognitive performance in animal 
models of brain aging
•	 protects ATPase activity of mitochondrial and membrane 
Na+/K+ ATPase
•	 inhibits phospholipase A2 activation and accelerates the 
reabsorption of cerebral edema in various experimental 
models.6
In some studies of patients with head trauma, citicoline 
has shown its capability at accelerating recovery from post-
traumatic coma (including the ability to walk), reaching 
better functional outcomes, reducing the duration of hospital 
stays, and to the improvement of memory and cognitive 
impairment.6 In the treatment of patients with acute ischemic 
vascular disease, citicoline accelerates the recovery of con-
sciousness and motor deficits, facilitating the rehabilitation 
of these patients.4,8–10 Another important use of CDP-choline 
is in the treatment of cognitive impairment secondary to 
age-related degenerative diseases (eg, Alzheimer’s disease) 
and chronic cerebrovascular disease.2,3 In patients with 
chronic cerebral ischemia the use of CDP-choline has been 
shown to improve scores on cognitive evaluation ranges, 
while in patients with Alzheimer’s senile dementia, it slows 
down disease progression. Beneficial neuroendocrine, neu-
rophysiological, and neuroimmunomodulatory effects in 
  Parkinson’s disease have also been reported, thanks to its 
indirect dopamine-agonist effect.11–14
The evidence is definitely strong, although limited 
by the duration of studies, so it would be appropriate 
to perform more long-term studies. Moreover, it can be 
assumed that long-term treatment is safe because serious 
side effects have never been reported. On the other hand, 
citicoline has no significant systemic cholinergic effects.6 
Therefore, we can summarize that citicoline may be used in 
cerebrovascular diseases, head trauma, cognitive disorders 
of different etiology, glaucoma, Parkinson’s disease, and 
amblyopia.
Aims
The aim of the present study was to evaluate the safety, toler-
ability, and efficacy of citicoline in geriatric syndrome8 with 
a complex clinical picture of confusion on a retrospective 
and observational basis.
Methods
The study involved ten centers throughout the country 
performing both geriatric surgery and home visits. Over 
65-year-olds with moderate to severe neurological deficits 
due to cerebral ischemia were enrolled.9,10,15,17 The fol-
lowing scales were administered: the National Institute 
of Health Stroke Scale (NIHSS),19–21 Rankin Scale (modi-
fied   version), and Barthel Index.16,18 The enrolled patients 
needed to have NIHSS 8–14/.15, Rankin Scale 4–5, and 
Barthel Index 40–20/,20. Those enrolled were people with 
progressive worsening of their cognitive health and general 
confusion and/or stupor (requiring the intervention of a 
geriatrician either in a nursing home or for home visits). All 
patients were over 65-years old and could not be   hospitalized. 
The study was divided into three phases in a period of 
6 months (Table 1). During the first phase (T1), which lasted 
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Table 1 Study design
1st phase enrollment 2nd phase post-acute 3rd phase conclusion
Step A (5 days)    (IV citicoline 2 gr in saline 500 cc) Step A (21 days)    (IM citicoline 1 gr) Outcome evaluation
Responders    2nd Phase Suspension (7 days)
Non-responders   	1st phase step B Step B (21 days)    (IM citicoline 1 gr)
Step B (5 days)    (IV citicoline 2 gr in saline 500 cc)
Responders   	2nd phase
Non-responders    Stop
4 months, patients were enrolled and treated with 2000 mg 
of citicoline through a slow intravenous infusion in 500 cc of 
saline for 5 days, to be repeated for 5 more days in the case 
of   nonresponders. In the second phase (T2), after clinical 
reassessment and verification of side effects and tolerability, 
(Step A) treatment with 1000 mg of intramuscular citicoline 
was administered and it was repeated for 21 days (Step B) 
after a 7 day interruption. During the third and final phase 
(T3) the results were evaluated. The NIHSS, the Rankin 
Scale, the Scale of Independence in Activities of Daily Liv-
ing (ADL), and the Scale of Independence in Instrumental 
Activities of Daily Living (IADL) were identified as tools for 
assessing deficits in autonomy, for their validity, reliability, 
and quick performance.
Demographic and clinical information about the patients 
included in the study were collected in forms filled in during 
the described phases and conveyed to a central database. The 
statistical processing of such data was made through the use 
of SPSS (IBM, Armonk, NY).
Results
A total of 272 subjects were enrolled. Of these, 197 sub-
jects (72%) were recruited and completed treatment and 
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Figure 1 Total sample.
  assessment, (43.1% men, 57.9% women), of which 55 (20%) 
were given the treatment provided during Stage T1, Step B 
(Figure 1).
A total of 75 patients (27%) dropped out of the study, 
five (1.8%) refused to continue treatment, and 70 (25%) 
gave up the study protocol or dropped out for other 
  reasons. The average age of the enrolled sample was 81.5 
years ± standard deviation. Frequency analysis by age group 
(Table 2) shows five subjects (2.5%) aged 60–69 years, 
78 subjects (39.6%) aged 70–79 years, 106 subjects (53.8%) 
aged 80–89 years, and eight subjects (4.1%) over 90 years 
old. The sample distribution by age group was conditioned 
only by the time limit of the first phase of recruitment and, 
therefore, features a real sample, which turns out to be better 
represented by the group of subjects aged 80–89 years.   
This demonstrates that age is significantly related to the 
complex geriatric syndrome. The analysis of diseases 
detected on history is confirmed by   epidemiological data 
in literature, and hypertension seems to be the most repre-
sented risk   factor. The association of dementia-hyperten-
sion-non-insulin dependent diabetes mellitus and coronary 
artery disease seem to exacerbate the development of this 
syndrome (Table 3).
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Table 4 Sample group – mean and standard deviation
Assessment scale 1st phase 2nd phase 3rd phase
National Institute of health  
Stroke Scale
13.6 ± 4.7* 11.1 ± 6* 11.1 ± 4.6
Rankin Scale 4.3 ± 0.7* 4.0 ± 0.7* 3.7 ± 0.7*
Activities of Daily Living 1.3 ± 1.3* 1.7 ± 1.3* 2.0 ± 1.4
Instrumental Activities  
of Daily Living
1.9 ± 2.4 2.1 ± 2.4 2.3 ± 2.5
Note: *P , 0.005.
Table 5 Control group – mean and standard deviation
Assessment scale 1st phase 2nd phase 3rd phase
National Institute of health  
Stroke Scale 12
20.2 ±	3.2 17.9 ±	4.9 17.7 ±	5.3
Rankin Scale   4.7 ±	0.5   4.6 ±	0.7   4.5 ±	0.7
Activities of Daily Living   0.3 ±	0.5   0.5 ±	0.7   0.5 ±	0.7
Instrumental Activities  
of Daily Living
  0.0 ±	0.0   0.1 ±	0.5   0.2 ±	0.6
Note: P , 0.005.
Table 2 Characterization of sample group
Demographics
Sample group Control group
n patients % n patients %
Female 112 56.9 8 53.3
Male 85 43.1 7 46.6
Age (years) 81.5 86.7
Age group
  60–69 5 2.5 2 13.3
  70–79 78 39.6 2 13.3
  80–89 106 53.8 5 33.3
 $ 90 8 4.1 6 40.0 of the starting values were higher and the age group was 
lower (60–69 years old). However, our results were also 
significant in the oldest age groups, because of age-related 
medical conditions (Figure 2). In short, the data must be 
read considering both the age group’s starting point and its 
therapeutic-rehabilitative goals.
The assessment with the Rankin scale shows a reduced 
improvement in self-sufficiency in those aged 70–79 years 
and 80–89 years, whereas changes in the first and last age 
groups are negligible. In this case, too, the assessment must 
consider the starting values since the study samples’ Rankin 
values already showed the presence of moderate to severe 
disabilities which can hardly regress (Figure 3).
Even ADL data (Figure 4) displayed a positive trend in 
the performance of functional independence in the sample 
group aged over 90 years old. ADLs also improved in all 
age groups (Figure 5).
Discussion
The examination of the final results shows statistical signifi-
cance, confirming the efficacy of citicoline in the complex 
geriatric syndrome complicated by confusion due to the 
worsening of general health conditions for the NIHSS dur-
ing T1–T2, the Rankin Scale during T1–T2–T3, and ADL 
Scale during T1–T2. There was no significance in IADL 
scores. However, the lack of statistical significance of our 
data, compared to a positive trend, requires further studies 
and a larger sample size.
Table 3 Sample group – comorbidity
Comorbidity n patients %
hypertension 145 73.6
Dementia 73 37.1
Non-insulin dependent diabetes mellitus 57 28.9
Coronary artery disease 35 17.8
Chronic obstructive pulmonary disease 17 8.6
Parkinson’s disease 15 7.6
Dyslipidemia 5 2.5
Benign prostate hypertrophy 4 2.0
Stroke 4 2.0
Depression 4 2.0
Chronic atrial fibrillation 4 2.0
hyperthyroidism 1 0.5
hip fracture 1 0.5
Chronic renal failure 1 0.5
The results were compared with a control group whose 
mean age was 86.7 years ± standard deviation; it included 
eight men (54%) and seven women (46%; Table 2). 
The control group was treated with intravenous admin-
istration of saline (500 cc) and glucose 5% (500 cc) and 
limited to 15 cases where treatment did not seem to result 
in significant clinical   improvement. In particular, mean 
NIHSS score was 19 and 18.2 during T1 and T3 respec-
tively, mean Rankin score was 4.7 and 4.5 during T1 and 
T3 respectively, mean ADL was 0.5 and 0.7 during T1 and 
T3 respectively, and mean IADL was 0.0 and 0.3 during 
T1 and T3 respectively (Table 4). The comparison with the 
sample group certainly indicates more favorable outcomes 
in the treated group, even though the small sample size 
of the controls does not provide a statistically significant 
difference (Table 5).
Data analysis of the NIHSS scale by age group shows 
an improvement in all phases and in all age groups. The 
positive results are particularly evident from T1 to T2: many 
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Figure 2 Sample group – National Institute of health Stroke Scale (NIhSS) by age group.
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Figure 3 Sample group – mean Rankin scores.
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Figure 4 Sample group – mean Activities of Daily Living (ADL) scores.
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Figure 5 Sample group – mean Instrumental Activities of Daily Living (IADL) scores.
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Conclusions
•	 In sub-acute ischemic cerebrovascular disease, adminis-
tration of citicoline at the intravenous dose of 2000 mg 
in 500 cc of saline for 5 days or 10 days has proven to 
be effective in improving functional independence and 
in reducing the burden of care.
•	 After 5 days (80% of cases), or 10 days (20% of cases; T2), 
or 2 months (T3) since the beginning of treatment, there 
was an improvement in key measures of performance. 
This was more evident in the younger old-age groups. 
The most important and significant positive impact was 
evident in the results of the oldest age groups.
•	 There were no major side effects in any phase of the study, 
so we can conclude that citicoline at the commonly used 
dosages is safe and well-tolerated.
•	 The association dementia–hypertension–non-insulin 
dependent diabetes mellitus–coronary artery disease 
is very much related to the development of complex 
geriatric syndrome complicated by confusion, and this 
leads us to reflect on the need for aggressive preventive 
therapies in advanced age too.
•	 The presence of dementia is associated with cardio-
cerebrovascular risk factors and the reconsideration on 
epidemiological data of degenerative dementias.
•	 The “complex geriatric syndrome” is significantly related 
to a condition of “frailty” that is, in turn, related to age.
•	 The results must consider the poor sample size, the short 
follow-up, and its features of being a retrospective and 
observational study.
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